Drug

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status
CancerSynRx Therapeutics

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

SynRx Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SYN818, the company's proprietary Polθ (DNA polymerase theta) inhibitor, in combination with…

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
ADC / XDCBiocytogen Pharmaceuticals

Biocytogen’s NEOK002 Wins FDA Approval for Phase I – EGFR/MUC1 Bispecific ADC Targets Solid Tumors

Clinical trial approval / initiationJoincare Pharmaceutical

Joincare Pharma’s JKN2404 Wins NMPA Approval for Asthma Trial – Next-Gen Inhaled Corticosteroid Targets Improved Safety Profile

PulmongeneRare / orphan disease drugs

Pulmongene’s PMG1015 Wins FDA Fast Track Designation – First-in-Class AREG Antibody Targets Idiopathic Pulmonary Fibrosis

HKG: 0950Lee's Pharmaceutical

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Show More